ArticleCancers2020
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.1field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 24 citations in OpenAlex.
- Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers.JNCI cancer spectrum · 2024Trial
- Recent Advances in CRISPR/Cas Technologies for Biological Discovery, Therapeutics, and Diagnostics.Biomolecules · 2026Review
- Mechanisms of Metabolic Reprogramming Regulating Immunosuppression in the Gastric Cancer Tumor Microenvironment.Biomolecules · 2026Review
- Computational screening of oncogenic genetic variations in tumor suppressor proteins driving gastric cancer pathogenesis.PloS one · 2026Article
- CRISPR/Cas9 gene editing in gastric cancer: Mechanisms, advances, and therapeutic potential.World journal of gastrointestinal pathophysiology · 2025Review
- ATR-CHK1 Axis Inhibitors in Gastric Cancer Treatment.International journal of molecular sciences · 2025Review
- Fuelling the Fight from the Gut: Short-Chain Fatty Acids and Dexamethasone Synergise to Suppress Gastric Cancer Cells.Cancers · 2025Article
- Targeting Gastrointestinal Cancers with Carvacrol: Mechanistic Insights and Therapeutic Potential.Biomolecules · 2025Review
- Clinical impact of TP53 functional mutations in patients with metastatic colorectal cancer treated with bevacizumab and chemotherapy.The oncologist · 2025Article
- The value of nucleoporin 188 in diagnosis, prognosis and immunoregulation: from pan-cancer analysis to gastric cancer verification.Frontiers in immunology · 2025Article
- Herbs and their Active Constituents for Gastric Cancer and Related Problems - Preclinical and Clinical Studies.Current protein & peptide science · 2025Review
- Molecular Classifications in Gastric Cancer: A Call for Interdisciplinary Collaboration.International journal of molecular sciences · 2024Review
- Clinical and Genetic Characteristics of Early and Advanced Gastric Cancer.Current issues in molecular biology · 2024Article
- Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2022Article
- Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status.The oncologist · 2022Article
- Identification and Verification of SLC27A1, PTBP1 and EIF5A With Significantly Altered Expression in Aggressive Pituitary Adenomas.Frontiers in surgery · 2022Article
- Identification of Stemness Characteristics Associated With the Immune Microenvironment and Prognosis in Gastric Cancer.Frontiers in oncology · 2021Article
- Her4 in gastric adenocarcinoma and its association with molecular prognostic markers Ki-67 proliferation index and p53 mutational status in Saudis: A study at a tertiary care hospital in Eastern Saudi Arabia.Journal of family & community medicineArticle
- A novel 8-genome instability-associated lncRNAs signature predicting prognosis and drug sensitivity in gastric cancer.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 11 institutions in 2 countries.
Francesco GrazianoMedical Oncology Unit, Azienda, Ospedali Riuniti Marche Nord, 61121 Pesaro, Italy.
Nicholas W FischerGenetics & Genome Biology Program, The Hospital for Sick Children, Toronto, ON M5G 0A4, Canada.
Irene BagaloniDepartment of Biomolecular Sciences, Università degli Studi di Urbino, 61032 Fano, Italy.
Maria Di BartolomeoDepartment of Medical Oncology, Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy.
Sara LonardiVeneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy.ORCID 0000-0002-7593-8138
Bruno VincenziDepartment of Oncology, Campus Bio-Medico University, 00128 Rome, Italy.
Giuseppe PerroneDepartment of Oncology, Campus Bio-Medico University, 00128 Rome, Italy.
Lorenzo FornaroUnit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, 56126 Pisa, Italy.ORCID 0000-0002-0187-5904
Elena OngaroDepartment of Oncology, University and General Hospital, 33100 Udine, Italy.
Giuseppe AprileDepartment of Oncology, San Bortolo General Hospital, 36100 Vicenza, Italy.
Renato BisonniMedical Oncology Unit, Hospital of Fermo, 63900 Fermo, Italy.
Michele PrisciandaroDepartment of Medical Oncology, Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy.ORCID 0000-0001-5596-469X
David MalkinGenetics & Genome Biology Program, The Hospital for Sick Children, Toronto, ON M5G 0A4, Canada.
Jean GariépyDepartment of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada.
Matteo FassanVeneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy.ORCID 0000-0001-6515-5482
Fotios LoupakisVeneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy.
Donatella SartiMedical Oncology Unit, Azienda, Ospedali Riuniti Marche Nord, 61121 Pesaro, Italy.
Michela Del PreteMedical Oncology Unit, Hospital of Fermo, 63900 Fermo, Italy.
Vincenzo CatalanoMedical Oncology Unit, Azienda, Ospedali Riuniti Marche Nord, 61121 Pesaro, Italy.
Paolo AlessandroniMedical Oncology Unit, Azienda, Ospedali Riuniti Marche Nord, 61121 Pesaro, Italy.
Mauro MagnaniDepartment of Biomolecular Sciences, Università degli Studi di Urbino, 61032 Fano, Italy.ORCID 0000-0001-6456-6626
Annamaria RuzzoDepartment of Biomolecular Sciences, Università degli Studi di Urbino, 61032 Fano, Italy.ORCID 0000-0003-2815-1890
Ospedali Riuniti Marche Nord · ITIstituto Oncologico Veneto · ITUniversity of Urbino · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITUniversità Campus Bio-Medico · ITAzienda Ospedaliera Universitaria Pisana · ITHospital for Sick Children · CAOspedale San Bortolo · ITSunnybrook Health Science Centre · CAUniversity of Toronto · CAUniversity of Udine · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
Loss of p53 promotes vascular endothelial growth factor (VEGF)-A up-regulation and the angiogenic potential of cancer cells. We investigated
Indexed as
angiogenesisgastric cancerPaclitaxelRamucirumabTP53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.